Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
(
1 selected
)
Type
Guidance (325)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (16)
Highly specialised technologies guidance (9)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (325)
Apply filters
Showing 201 to 250 of 325
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]
Technology appraisal guidance
20 August 2025
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]
Technology appraisal guidance
TBC
Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]
Technology appraisal guidance
TBC
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]
Technology appraisal guidance
TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
Technology appraisal guidance
TBC
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]
Technology appraisal guidance
16 July 2025
Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]
Technology appraisal guidance
TBC
Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594
Technology appraisal guidance
TBC
Pegcetacoplan for treating geographic atrophy [ID4041]
Technology appraisal guidance
TBC
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]
Technology appraisal guidance
TBC
Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]
Technology appraisal guidance
20 November 2024
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473
Technology appraisal guidance
TBC
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]
Technology appraisal guidance
11 December 2024
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Technology appraisal guidance
TBC
Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]
Technology appraisal guidance
TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]
Technology appraisal guidance
TBC
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]
Technology appraisal guidance
TBC
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]
Technology appraisal guidance
TBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]
Technology appraisal guidance
TBC
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]
Technology appraisal guidance
TBC
Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]
Technology appraisal guidance
TBC
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]
Technology appraisal guidance
TBC
Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]
Technology appraisal guidance
TBC
Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]
Technology appraisal guidance
TBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]
Technology appraisal guidance
TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]
Technology appraisal guidance
TBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]
Technology appraisal guidance
TBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]
Technology appraisal guidance
28 May 2025
Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]
Technology appraisal guidance
TBC
Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381
Technology appraisal guidance
16 April 2025
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]
Technology appraisal guidance
TBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]
Technology appraisal guidance
TBC
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]
Technology appraisal guidance
TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
Technology appraisal guidance
TBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]
Technology appraisal guidance
TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
Technology appraisal guidance
TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
Technology appraisal guidance
TBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353
Technology appraisal guidance
TBC
Port Delivery System with ranibizumab for treating wet age-related macular degeneration [ID3983]
Technology appraisal guidance
TBC
Pralsetinib for thyroid cancer [ID4018]
Technology appraisal guidance
TBC
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
Technology appraisal guidance
15 November 2017
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982]
Technology appraisal guidance
TBC
Renal cell carcinoma Pathways Pilot [ID6186]
Technology appraisal guidance
TBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]
Technology appraisal guidance
TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007
Technology appraisal guidance
TBC
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)
Technology appraisal guidance
TBC
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]
Technology appraisal guidance
18 June 2025
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Technology appraisal guidance
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Technology appraisal guidance
TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]
Technology appraisal guidance
TBC
Previous page
1
…
3
4
Current page
5
6
7
Page
5
of
7
Next page
Results per page
10
25
50
All
Back to top